| 产品描述: | ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC50s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis. |
| 体外研究: |
ZC0109 (15, 30, and 60 mg/kg; p.o.; once daily for 28 d) reduces Kyn/Trp metabolism in C57BL/6 mice. ZC0109 (60 mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplanted immunocompetent BALB/c mice. |
| 体内研究: |
ZC0109 (24 h) inhibits cancer cells with IC50s of 3.44 μM (HCT-116), 12.4 μM (CT26), and 10.2 μM (HeLa), respectively. ZC0109 (2.5-10 μM; 24 h) induces ROS accumulation in HCT-116 and HeLa cells. ZC0109 (2.5-10 μM; 24 h) induces apoptosis and G1/S cell cycle arrest in cancer cell. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.691 ml |
8.454 ml |
16.909 ml |
| 5 mM |
0.338 ml |
1.691 ml |
3.382 ml |
| 10 mM |
0.169 ml |
0.845 ml |
1.691 ml |
| 50 mM |
0.034 ml |
0.169 ml |
0.338 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |